EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Status and Progress of Targeted and Immunotherapy for DSRCT

Tian Wei, Qidi Zhao iD, Yan Li

Cancers · 24.05.2026 · 18 (11) · 1711

DOI: 10.3390/cancers18111711 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.05.2026. Verfasst von Tian Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Peritoneal Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing …. Die Arbeit nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Desmoplastic small round cell tumor (DSRCT) is a rare and highly malignant tumor that mostly occurs in young males. Due to its extremely strong invasiveness and poor prognosis, the treatment of DSRCT remains a major challenge in current medical research. The comprehensive treatment strategy based on surgery, combined with chemotherapy, targeted therapy, immunotherapy has become a clinical consensus. This review summarizes the main pathogenic mechanisms of DSRCT, as well as the targets involved in treatment and their applications, including targeted therapy targets (PDGF, VEGFR, FGFR4, IGF1R, HER2, c-KIT, mTOR, AR), immunotherapy targets (PD-1, PD-L1, B7H3, GD2), and treatments related to DNA damage response. Studies have shown that treatments targeting specific targets can inhibit tumor progression and prolong patient survival to a certain extent, but the efficacy has individual differences and is still limited. Therefore, future research still needs to further explore the molecular mechanism of DSRCT and discover more accurate and effective therapeutic targets.

Schlagwörter

Stichwörter der Autor:innen

DNA damage response (DDR)EWSR1-WT1desmoplastic small round cell tumor (DSRCT)immunotherapytargeted therapy

Autor:innen und Institutionen

  • Department of Peritoneal Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China.

ORCID-Profile: Qidi Zhao

Zitieren

APA

Wei, T., Zhao, Q., & Li, Y. (2026). Current Status and Progress of Targeted and Immunotherapy for DSRCT. Cancers, 18(11), 1711. https://doi.org/10.3390/cancers18111711

Vancouver

Wei T, Zhao Q, Li Y. Current Status and Progress of Targeted and Immunotherapy for DSRCT. Cancers. 2026;18(11):1711. doi:10.3390/cancers18111711

BibTeX
@article{Wei2026,
  author = {Wei, Tian and Zhao, Qidi and Li, Yan},
  title = {Current Status and Progress of Targeted and Immunotherapy for DSRCT},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1711},
  doi = {10.3390/cancers18111711}
}
Kostenlos starten →